# Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

> **NCT02558348** · PHASE1,PHASE2 · TERMINATED · sponsor: **Advenchen Laboratories, LLC** · enrollment: 12 (actual)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer
- Cervical Cancer

## Interventions

- **DRUG:** AL3818

## Key facts

- **NCT ID:** NCT02558348
- **Lead sponsor:** Advenchen Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2017-02-14
- **Final completion:** 2017-05-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor termination
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558348, "Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02558348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*